newsfilter
← Latest News
Business Wire·

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test of attention – –